Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNRPE siRNA
- Development stage
- Preclinical
- Lead developer
- Gustave Roussy
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
SNRPE siRNA is a small interfering RNA (siRNA) designed to target and downregulate the expression of small nuclear ribonucleoprotein polypeptide E (SNRPE), a core component of the spliceosome assembly. In preclinical oncology research, siRNA-mediated knockdown of SNRPE has been shown to inhibit cell proliferation, downregulate the mTOR pathway, and induce autophagy or pyroptosis in various cancer cell lines, including breast, prostate, lung, and melanoma cancers. The therapeutic concept of targeting SNRPE with siRNA was pioneered by researchers at the Institut Gustave Roussy.
- Other names
- small nuclear ribonucleoprotein E siRNAsmall nuclear ribonucleoprotein polypeptide E siRNA
02
Targets
Small nuclear ribonucleoprotein polypeptide E mRNAmTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on SNRPE siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNRPE siRNA.